media1

Group News

Dr. Judy Dlamini appointed chairman designate at Aspen

June 11, 2006

Dr Judy Dlamini will succeed Archie Aaron as chairman of the board of directors of Aspen Pharmacare Holdings Limited (“Aspen”) after Aspen’s annual general meeting of shareholders which is scheduled to take place in November 2007. Archie Aaron has decided to step down as chairman having served in this position since 1999. He will remain…

Read More >>

Aspen to manufacture influenza medicine oseltamivir

May 16, 2006

Aspen (APN), South Africa’s largest listed pharmaceutical company, today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche’s continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic…

Read More >>

Aspen signs MOU for TB products

March 2, 2006

Johannesburg – JSE listed Aspen (APN) and Indian based Lupin Limited have entered into a Memorandum of Understanding for the establishment of a 50:50 joint venture for the development, manufacture and global marketing of selected anti-tuberculosis (TB) products. The JV will also investigate opportunities to enter the Malaria market. Stephen Saad, Aspen Group Chief Executive…

Read More >>

Aspen records 45% increase in HEPS

February 27, 2006

Aspen records 45% increase in HEPS Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded impressive interim results for the period ended December 2005. Headline earnings per share (HEPS) increased 45 percent to 86.3 cents (59.4 cents). Revenue increased by 27 percent to R1,687 billion (R1.4 billion). Operating profit rose 34 percent…

Read More >>

Aspen and BMS conclude strategic ARV deal

February 15, 2006

JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer and the largest generic manufacturer in the southern hemisphere, has signed a non-exclusive license and technology transfer collaboration agreement with New York based Bristol-Myers Squibb (BMS) for the manufacture and distribution of a generic version of Atazanavir, a new generation anti-retroviral (ARV). BMS selected Aspen…

Read More >>

Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs

January 1, 2006

Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30-50 Percent for 50 Countries Clinton Also Confirms that Nearly a Quarter-Million People Living with HIV are Benefiting from First-Line HIV/AIDS Drug Agreements his…

Read More >>

Aspen Opens R1 million Wellness Centre

November 25, 2005

JSE listed Aspen Pharmacare, Africa’s largest pharmaceutical manufacturer and the leading global player in generic anti-retrovirals (ARVs), earlier today opened a R1 million wellness centre in the Eastern Cape. Through a public-private partnership, Aspen’s investment in the establishment of the Wells Estate Wellness Centre will enhance the primary healthcare services at the Nelson Mandela Bay…

Read More >>

Aspen and Lupin sign TB deal

September 26, 2005

JSE listed Aspen Pharmacare Holdings Limited and Lupin Limited of India have entered into an agreement to collaborate in the tuberculosis (TB) related products market in South Africa. The agreement involves cooperation in the areas of technology, manufacture and marketing. Stephen Saad, Aspen Group Chief Executive said, “the agreement enhances South Africa and Aspen’s ability…

Read More >>

Aspen and India’s Matrix sign JVs

September 23, 2005

Aspen Pharmacare Holdings Limited (Aspen) has signed definitive joint venture (JV) agreements with Indian-based Matrix Laboratories Limited (Matrix). The deals strengthen Aspen’s vertical integration into the manufacture of Active Pharmaceutical Ingredients (APIs), the key raw materials required in the manufacture of finished dosage form pharmaceuticals including anti-retrovirals (ARVs), and they unlock additional global supply and…

Read More >>